g - Search

Clinical Trials

• G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
  ClinicalTrials.gov Identifier: NCT00082329 - Recruiting
  Healthy
  
• G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00554463 - Not yet recruiting
  Lung Cancer
  
• G-CSF for Granulocyte Donation
  ClinicalTrials.gov Identifier: NCT00001842 - Completed
  Healthy
  
• G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00541125 - Not yet recruiting
  Colorectal Cancer
  
• G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
  ClinicalTrials.gov Identifier: NCT00233961 - Recruiting
  Leukemia
  
• G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome
  ClinicalTrials.gov Identifier: NCT00228813 - Recruiting
  Hematologic Malignancies
  
• G-CSF to Treat Crohn's Disease
  ClinicalTrials.gov Identifier: NCT00025805 - Recruiting
  Crohn's Disease
  
• G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response
  ClinicalTrials.gov Identifier: NCT00397423 - Completed
  Amyotrophic Lateral Sclerosis
  
• G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
  ClinicalTrials.gov Identifier: NCT00499343 - Active, not recruiting
  Lymphoma
  
• G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
  ClinicalTrials.gov Identifier: NCT00253552 - Active, not recruiting
  Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Sarcoma
  
• G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
  ClinicalTrials.gov Identifier: NCT00255645 - Completed
  Type 2 Diabetes
  
• G-Step: Gemcitabine Based Small-Cell Lung Cancer Treatment in Elderly Patients
  ClinicalTrials.gov Identifier: NCT00401609 - Active, not recruiting
  Small Cell Lung Cancer
  
• G207 Followed by Radiation Therapy in Malignant Glioma
  ClinicalTrials.gov Identifier: NCT00157703 - Recruiting
  recurrent/progressive malignant glioma
  
• G3139 and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00004870 - Completed
  recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ...
  
• Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors
  ClinicalTrials.gov Identifier: NCT00569738 - Not yet recruiting
  Neuroendocrine Tumor
  
• GABA Levels in the Brains of Blind People
  ClinicalTrials.gov Identifier: NCT00357409 - Recruiting
  Vision; Blind
  
• GABA Medications for Cocaine Addiction - 3
  ClinicalTrials.gov Identifier: NCT00142883 - Terminated
  
  
• GABA-A alpha2/3 Study
  ClinicalTrials.gov Identifier: NCT00129441 - Active, not recruiting
  Schizophrenia
  
• Gabapentin - A Solution to Uremic Pruritus?
  ClinicalTrials.gov Identifier: NCT00577967 - Not yet recruiting
  Pruritus; Uremia
  
• Gabapentin for Carpal Tunnel Syndrome
  ClinicalTrials.gov Identifier: NCT00137735 - Completed
  Carpal Tunnel Syndrome
  
• Gabapentin for Postoperative Pain Management After Cardiac Surgery With Median Sternotomy
  ClinicalTrials.gov Identifier: NCT00572208 - Not yet recruiting
  Pain, Postoperative
  
• Gabapentin for Smoking Cessation
  ClinicalTrials.gov Identifier: NCT00578552 - Recruiting
  Cigarette Smoking; Tobacco Use
  
• Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
  ClinicalTrials.gov Identifier: NCT00022074 - Active, not recruiting
  Anxiety Disorder; Breast Cancer; Depression; Hot Flashes; Quality of Life
  
• Gabapentin for the Treatment of Hot Flashes in Menopausal Women
  ClinicalTrials.gov Identifier: NCT00112138 - Active, not recruiting
  Hot Flashes; Menopause
  
• Gabapentin for the Treatment of Neuroleptic-Induced Tremor
  ClinicalTrials.gov Identifier: NCT00533455 - Terminated
  Neuroleptic-Induced Tremor
  
• Gabapentin for the Treatment of Tinnitus
  ClinicalTrials.gov Identifier: NCT00317850 - Terminated
  Tinnitus
  
• Gabapentin in Fibromyalgia Trial (GIFT)
  ClinicalTrials.gov Identifier: NCT00057278 - Completed
  Fibromyalgia
  
• Gabapentin in Phantom and Stump Pain
  ClinicalTrials.gov Identifier: NCT00169013 - Completed
  Amputation of Lower Limb
  
• Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00028574 - Active, not recruiting
  stage I prostate cancer; stage II prostate cancer; stage III prostate cancer; stage IV prostate cancer; recurrent prostate cancer; Hot Flashes
  
• Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
  ClinicalTrials.gov Identifier: NCT00027963 - Active, not recruiting
  neurotoxicity; Pain; Quality of Life
  
• Gabapentin to Treat Itch in Patients with Liver Disease
  ClinicalTrials.gov Identifier: NCT00058890 - Completed
  Liver Disease; Cholestasis; Cirrhosis; Pruritus; Itching
  
• Gabapentin Treatment of Alcohol Dependence
  ClinicalTrials.gov Identifier: NCT00391716 - Recruiting
  Alcoholism; Alcohol Abuse; Alcohol Dependence
  
• Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients
  ClinicalTrials.gov Identifier: NCT00420771 - Recruiting
  Benzodiazepine Dependence; Methadone Maintainance
  
• Gabapentin Treatment of Cannabis Dependence
  ClinicalTrials.gov Identifier: NCT00395044 - Recruiting
  Cannabis Dependence
  
• Gabapentin Versus Estrogen for the Treatment of Hot Flashes
  ClinicalTrials.gov Identifier: NCT00276081 - Completed
  Hot Flashes
  
• Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00087399 - Completed
  Breast Cancer; Hot Flashes
  
• Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00006452 - Active, not recruiting
  adult glioblastoma multiforme
  
• Gadolinium Texaphyrin With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
  ClinicalTrials.gov Identifier: NCT00003410 - Completed
  adult glioblastoma multiforme
  
• Gait Adaptations to Passive Dynamic Akle-Foot Orthosis Use
  ClinicalTrials.gov Identifier: NCT00115401 - Completed
  
  
• Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
  ClinicalTrials.gov Identifier: NCT00331747 - Recruiting
  Multiple Sclerosis
  
• Gait Evaluation of Experienced Below Knee Amputees
  ClinicalTrials.gov Identifier: NCT00353626 - Recruiting
  Amputations, Traumatic
  
• Gait Trainer Vs Traditional Physiotherapy in Acute Stroke
  ClinicalTrials.gov Identifier: NCT00307762 - Completed
  Patients With Acute Stroke
  
• Gait Training and Brain Changes in Stroke Patients
  ClinicalTrials.gov Identifier: NCT00334230 - Recruiting
  Gait Training; Locomotion
  
• Gait Training For Acute Stroke: Functional Neuromuscular Stimulation (FNS) and Weight Supported Treadmill Training
  ClinicalTrials.gov Identifier: NCT00101543 - Recruiting
  Stroke
  
• Galantamine Augmentation of Escitalopram for Treatment of Depression
  ClinicalTrials.gov Identifier: NCT00423969 - Terminated
  Depression
  
• Galantamine Executive Function in Parkinson's Disease
  ClinicalTrials.gov Identifier: NCT00211588 - Active, not recruiting
  Parkinson's Disease
  
• Galantamine for Cognition in People With Schizophrenia
  ClinicalTrials.gov Identifier: NCT00320736 - Active, not recruiting
  Schizophrenia; Schizoaffective Disorder
  
• Galantamine for Cognitive Deficits in Schizophrenia
  ClinicalTrials.gov Identifier: NCT00463879 - Completed
  Schizophrenia
  
• Galantamine in the Treatment of Post-Traumatic Headache
  ClinicalTrials.gov Identifier: NCT00219869 - Recruiting
  Post-Traumatic Headache; Head Trauma,Closed; Retention Disorders,Cognitive
  
• Galantamine Versus Placebo in Childhood Autism
  ClinicalTrials.gov Identifier: NCT00252603 - Completed
  Autism; Childhood Autism
  
• Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder
  ClinicalTrials.gov Identifier: NCT00181636 - Completed
  Bipolar Disorder
  
• Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00516217 - Not yet recruiting
  Lymphoma
  
• GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
  ClinicalTrials.gov Identifier: NCT00261352 - Completed
  Type 2 Diabetes
  
• GALLANT 2 Tesaglitazar vs. Placebo
  ClinicalTrials.gov Identifier: NCT00252772 - Completed
  Type 2 Diabetes
  
• GALLANT 22 Tesaglitazar vs. Placebo
  ClinicalTrials.gov Identifier: NCT00252837 - Completed
  Type 2 Diabetes
  
• GALLANT 4 Tesaglitazar vs. Glibenclamide
  ClinicalTrials.gov Identifier: NCT00255541 - Completed
  Type 2 Diabetes
  
• GALLANT 5 Tesaglitazar Versus Metformin
  ClinicalTrials.gov Identifier: NCT00214591 - Completed
  Diabetes Mellitus, Type 2
  
• GALLANT 6 Tesaglitazar Vs. Pioglitazone
  ClinicalTrials.gov Identifier: NCT00214565 - Completed
  Diabetes Mellitus, Type 2
  
• GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
  ClinicalTrials.gov Identifier: NCT00251940 - Completed
  Type 2 Diabetes
  
• GALLANT 8 Tesaglitazar Add-on to Metformin
  ClinicalTrials.gov Identifier: NCT00251953 - Completed
  Type 2 Diabetes
  
• GALLANT 9 Tesaglitazar Vs. Placebo in Combination With Insulin
  ClinicalTrials.gov Identifier: NCT00242372 - Completed
  Type 2 Diabetes Mellitus
  
• Gallbladder Cholesterolosis, Body Mass Index and Serum Cholesterol and Triglycerides
  ClinicalTrials.gov Identifier: NCT00528632 - Not yet recruiting
  Gallstones; Gallbladder Cholesterolosis; Serum Cholesterol and Triglycerides; Body Mass Index
  
• GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes
  ClinicalTrials.gov Identifier: NCT00252876 - Completed
  Type 2 Diabetes
  
• GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes
  ClinicalTrials.gov Identifier: NCT00300105 - Completed
  Type 2 Diabetes
  
• GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
  ClinicalTrials.gov Identifier: NCT00226330 - Completed
  Diabetes Mellitus, Type 2
  
• GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes
  ClinicalTrials.gov Identifier: NCT00229710 - Completed
  Diabetes Mellitus, Type 2
  
• Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00002543 - Completed
  recurrent childhood rhabdomyosarcoma; recurrent neuroblastoma; recurrent childhood large cell lymphoma; ...
  
• Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00002578 - Completed
  AIDS-related diffuse small cleaved cell lymphoma; AIDS-related small noncleaved cell lymphoma; AIDS-related lymphoblastic lymphoma; ...
  
• Gamma Interferon Therapy for Chronic Hepatitis C
  ClinicalTrials.gov Identifier: NCT00028275 - Completed
  Chronic Hepatitis C
  
• Gamma Vacuum Foil (GVF) Versus Cross-Linked Polyethylene in Total Knee Arthroplasty Study
  ClinicalTrials.gov Identifier: NCT00289133 - Active, not recruiting
  Osteoarthritis, Knee; Arthritis, Rheumatoid
  
• Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
  ClinicalTrials.gov Identifier: NCT00530218 - Active, not recruiting
  Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
  
• Ganciclovir Implant Study for Cytomegalovirus Retinitis
  ClinicalTrials.gov Identifier: NCT00000118 - Completed
  HIV Infections; Acquired Immunodeficiency Syndrome; Cytomegalovirus Retinitis
  
• Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
  ClinicalTrials.gov Identifier: NCT00264368 - Terminated
  Acute Renal Failure; Cytomegalovirus Infections; Multi Organ Failure
  
• Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated with the Epstein Barr Virus
  ClinicalTrials.gov Identifier: NCT00006340 - Completed
  Cancer; grade I lymphomatoid granulomatosis; grade II lymphomatoid granulomatosis; recurrent grade I lymphomatoid granulomatosis; ...
  
• Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
  ClinicalTrials.gov Identifier: NCT00002024 - Completed
  Cytomegalovirus Infections; HIV Infections
  
• Gardasil (V501) Study in Adult Women
  ClinicalTrials.gov Identifier: NCT00378560 - Active, not recruiting
  Papillomavirus Infections
  
• Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities
  ClinicalTrials.gov Identifier: NCT00501189 - Recruiting
  Papillomavirus Infections
  
• GARFT Inhibitor in Patients with Metastatic Non-Small Cell Lung Cancer who Failed Two or Three Prior Systemic Treatments
  ClinicalTrials.gov Identifier: NCT00090701 - Completed
  Metastatic Non-Small Cell Lung Cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Garlic in Hyperlipidemia Caused by HAART
  ClinicalTrials.gov Identifier: NCT00029250 - Terminated
  HIV Infections; Hypercholesterolemia; Hypertriglyceridemia; Hyperglycemia
  
• Garlic in Patients With Febrile Neutropenia
  ClinicalTrials.gov Identifier: NCT00247039 - Recruiting
  Post Chemotherapy Induced Febrile Neutropenia
  
• GAS Epi Study to Measure Age-Related Antibody Titers to J8 Vaccine
  ClinicalTrials.gov Identifier: NCT00264784 - Completed
  Streptococcus Group A
  
• Gas Kinetics and Metabolism in Anesthesia During Non Steady State
  ClinicalTrials.gov Identifier: NCT00225381 - Recruiting
  Anesthetized Healthy Patients(ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries; Anesthestized Patient With Severe Systemic Disease (ASA 3 or 4)
  
• Gas Supply, Demand and Middle Ear Gas Balance: Sp Aim 3a Pt ii
  ClinicalTrials.gov Identifier: NCT00494364 - Recruiting
  Healthy
  
• Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c
  ClinicalTrials.gov Identifier: NCT00422851 - Recruiting
  Healthy
  
• Gas Usage for Those With COPD Who Experience Low Oxygen Levels During Activities Only
  ClinicalTrials.gov Identifier: NCT00546299 - Completed
  Chronic Obstructive Pulmonary Disease
  
• Gases Humidification During Noninvasive Ventilation : Heat and Moisture Exchanger or Heated Humidifier ?
  ClinicalTrials.gov Identifier: NCT00221819 - Terminated
  Acute Lung Injury; Pneumonia; Chronic Obstructive Pulmonary Disease; Acute Heart Failure
  
• Gastrectomy Study
  ClinicalTrials.gov Identifier: NCT00160186 - Terminated
  Gastrectomy
  
• Gastric Motor Function Measurement in Dyspepsia and Normal Subjects
  ClinicalTrials.gov Identifier: NCT00296582 - Completed
  Dyspepsia
  
• Gastric Pacemaker Implantation for Gastroparesis
  ClinicalTrials.gov Identifier: NCT00568373 - Recruiting
  Gastroparesis
  
• Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass
  ClinicalTrials.gov Identifier: NCT00297245 - Recruiting
  Cognitive Decline
  
• Gastrointestinal and Health-Related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil
  ClinicalTrials.gov Identifier: NCT00400647 - Recruiting
  Maintenance Kidney Transplant
  
• Gastrointestinal and Health-Related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
  ClinicalTrials.gov Identifier: NCT00351377 - Recruiting
  Autoimmune Disease
  
• Gastrointestinal and Health-Related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants
  ClinicalTrials.gov Identifier: NCT00267150 - Recruiting
  Pancreas Transplantation; Kidney Transplantation
  
• Gastrointestinal Evaluation in Young Men With Iron Deficiency Anemia
  ClinicalTrials.gov Identifier: NCT00498511 - Not yet recruiting
  Anemia, Iron-Deficiency
  
• Gastrointestinal Stromal Tumors Registry
  ClinicalTrials.gov Identifier: NCT00507273 - Recruiting
  Gastrointestinal Stromal Tumors
  
• Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
  ClinicalTrials.gov Identifier: NCT00413309 - Active, not recruiting
  Acute Coronary Syndrome
  
• Gastroparesis Registry
  ClinicalTrials.gov Identifier: NCT00398801 - Recruiting
  Gastroparesis
  
• Gatekeeper European 005
  ClinicalTrials.gov Identifier: NCT00229086 - Terminated
  GERD
  
• GB/MF59 Vaccine in Preventing CMV Infection in Healthy Adolescent Females
  ClinicalTrials.gov Identifier: NCT00133497 - Recruiting
  Cytomegalovirus Infections
  
• GBR 12909 Study in Cocaine Experienced African American Volunteers - 1
  ClinicalTrials.gov Identifier: NCT00089687 - Active, not recruiting
  Cocaine-Related Disorders
  
• GCSSG-SPNX: Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma
  ClinicalTrials.gov Identifier: NCT00112099 - Recruiting
  Gastric Neoplasm
  
• GECO: Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00385606 - Completed
  Advanced Non-Small Cell Lung Cancer
  
• Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
  ClinicalTrials.gov Identifier: NCT00239304 - Completed
  Head and Neck Neoplasms
  
• Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00091156 - Recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00068653 - Active, not recruiting
  recurrent non-small cell lung cancer
  
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00052585 - Completed
  stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer; adenocarcinoma of the colon; ...
  
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00025142 - Active, not recruiting
  stage IV colon cancer; Stage IV rectal cancer; recurrent colon cancer; recurrent rectal cancer; adenocarcinoma of the colon; ...
  
• Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00084786 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
  ClinicalTrials.gov Identifier: NCT00483561 - Recruiting
  Prostate Cancer
  
• Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00096486 - Recruiting
  recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
  ClinicalTrials.gov Identifier: NCT00423397 - Recruiting
  Non-Melanomatous Skin Cancer
  
• Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00467077 - Recruiting
  Kidney Cancer
  
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
  ClinicalTrials.gov Identifier: NCT00042991 - Active, not recruiting
  untreated childhood brain stem glioma
  
• Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
  ClinicalTrials.gov Identifier: NCT00052208 - Active, not recruiting
  adult glioblastoma multiforme
  
• Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00033449 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Oropharyngeal Cancer
  
• Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00098462 - Recruiting
  recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00217698 - Active, not recruiting
  Lung Cancer
  
• Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
  ClinicalTrials.gov Identifier: NCT00082667 - Active, not recruiting
  breast cancer in situ; intraductal breast carcinoma
  
• Gefitinib in Combination With Chemoradiation in Resectable Gastric Cancer
  ClinicalTrials.gov Identifier: NCT00237900 - Terminated
  Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC
  
• Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
  ClinicalTrials.gov Identifier: NCT00241475 - Completed
  Prostate Cancer
  
• Gefitinib in Treating Children With Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00040781 - Completed
  unspecified childhood solid tumor, protocol specific
  
• Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
  ClinicalTrials.gov Identifier: NCT00126555 - Recruiting
  squamous cell carcinoma of the skin; recurrent skin cancer
  
• Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00104728 - Recruiting
  stage I non-small cell lung cancer; stage II non-small cell lung cancer; stage IIIA non-small cell lung cancer
  
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
  ClinicalTrials.gov Identifier: NCT00071994 - Active, not recruiting
  advanced adult primary liver cancer; recurrent adult primary liver cancer; adult primary hepatocellular carcinoma; ...
  
• Gefitinib in Treating Patients With Cervical Cancer
  ClinicalTrials.gov Identifier: NCT00049556 - Completed
  Cervical Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
  
• Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
  ClinicalTrials.gov Identifier: NCT00100945 - Active, not recruiting
  Adenocarcinoma of the Esophagus; stage II esophageal cancer
  
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
  ClinicalTrials.gov Identifier: NCT00052754 - Active, not recruiting
  adult synovial sarcoma; stage III adult soft tissue sarcoma; recurrent adult soft tissue sarcoma; stage IV adult soft tissue sarcoma
  
• Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
  ClinicalTrials.gov Identifier: NCT00095836 - Active, not recruiting
  anaplastic thyroid cancer; follicular thyroid cancer; medullary thyroid cancer; papillary thyroid cancer; Thyroid Cancer
  
• Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
  ClinicalTrials.gov Identifier: NCT00066339 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00068497 - Active, not recruiting
  Head and Neck Cancer; thorax and respiratory cancer
  
• Gefitinib in Treating Patients With Non-Small Cell Lung Cancer That Has Been Surgically Removed
  ClinicalTrials.gov Identifier: NCT00049543 - Active, not recruiting
  Non-small cell lung cancer
  
• Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00027690 - Active, not recruiting
  recurrent endometrial cancer
  
• Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00411047 - Active, not recruiting
  Lung Cancer
  
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
  ClinicalTrials.gov Identifier: NCT00075439 - Active, not recruiting
  Gastrinoma; gastrointestinal carcinoid tumor; Insulinoma; Islet Cell Carcinoma; metastatic gastrointestinal carcinoid tumor; ...
  
• Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00024089 - Active, not recruiting
  Head and Neck Cancer
  
• Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
  ClinicalTrials.gov Identifier: NCT00268346 - Recruiting
  Esophageal Cancer
  
• Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
  ClinicalTrials.gov Identifier: NCT00025675 - Active, not recruiting
  adult brain tumor
  
• Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00258297 - Recruiting
  Esophageal Cancer
  
• Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00029003 - Active, not recruiting
  recurrent non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; Bronchoalveolar Cell Lung Cancer
  
• Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00041106 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
  ClinicalTrials.gov Identifier: NCT00027625 - Completed
  recurrent adult brain tumor; adult glioblastoma multiforme; adult anaplastic astrocytoma; adult anaplastic oligodendroglioma; Mixed Gliomas
  
• Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00062062 - Active, not recruiting
  stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer
  
• Gefitinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00100854 - Active, not recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Gefitinib With or Without Simvastatin in NSCLC
  ClinicalTrials.gov Identifier: NCT00452244 - Recruiting
  Lung Cancer
  
• Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00080743 - Active, not recruiting
  recurrent breast cancer; stage IV breast cancer
  
• Gefitinib, Capecitabine, and Celecoxib in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00039390 - Completed
  unspecified adult solid tumor, protocol specific
  
• Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00290719 - Recruiting
  Esophageal Cancer
  
• Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00310154 - Active, not recruiting
  Lung Cancer
  
• Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00083057 - Active, not recruiting
  Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; ...
  
• Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00086957 - Recruiting
  stage IV breast cancer; Male Breast Cancer; recurrent breast cancer
  
• Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee
  ClinicalTrials.gov Identifier: NCT00450112 - Recruiting
  Osteoarthritis of the Knee
  
• Gel-200 Versus Placebo in Osteoarthritis of the Knee
  ClinicalTrials.gov Identifier: NCT00449696 - Active, not recruiting
  Osteoarthritis of the Knee
  
• Geldanamycin Analogue in Treating Patients With Advanced Cancer
  ClinicalTrials.gov Identifier: NCT00003969 - Completed
  unspecified adult solid tumor, protocol specific
  
• Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00019708 - Recruiting
  Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
  
• GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD
  ClinicalTrials.gov Identifier: NCT00546624 - Completed
  Anxiety Disorder
  
• GEM OS™1 Bone Graft Compared to Autologous Bone Graft in Foot and Ankle Fusions
  ClinicalTrials.gov Identifier: NCT00583375 - Recruiting
  Fusion
  
• GEM vs GEM+TS-1 for Advanced Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00514163 - Recruiting
  Pancreatic Cancer
  
• GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
  ClinicalTrials.gov Identifier: NCT00443235 - Recruiting
  Multiple Myeloma
  
• GEM05 for Patients With Multiple Myeloma Under 65 Years
  ClinicalTrials.gov Identifier: NCT00461747 - Recruiting
  Multiple Myeloma
  
• Gemcitabine (GEMZAR) Plus ABI-007 (ABRAXANE)In Patients With Advanced Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00398086 - Recruiting
  Advanced Metastatic Pancreatic Cancer
  
• Gemcitabine + Carboplatin in Breast Cancer
  ClinicalTrials.gov Identifier: NCT00450762 - Completed
  Breast Cancer
  
• Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00445601 - Recruiting
  Bladder Cancer
  
• Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas
  ClinicalTrials.gov Identifier: NCT00012220 - Active, not recruiting
  adenocarcinoma of the pancreas; stage IVB pancreatic cancer
  
• Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00410774 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine and Bortezomib in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00290706 - Suspended
  Lymphoma
  
• Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00316420 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
  ClinicalTrials.gov Identifier: NCT00084942 - Active, not recruiting
  cholangiocarcinoma of the gallbladder; recurrent gallbladder cancer; unresectable gallbladder cancer; ...
  
• Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
  ClinicalTrials.gov Identifier: NCT00058318 - Active, not recruiting
  Stage IV Renal Cell Cancer; stage III renal cell cancer
  
• Gemcitabine and Capecitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Gallbladder Cancer or Cholangiocarcinoma
  ClinicalTrials.gov Identifier: NCT00033540 - Active, not recruiting
  extrahepatic bile duct cancer; Gallbladder Cancer
  
• Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00425360 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00074204 - Active, not recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00276588 - Active, not recruiting
  Lung Cancer
  
• Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
  ClinicalTrials.gov Identifier: NCT00369954 - Not yet recruiting
  Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
  
• Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00326599 - Suspended
  Lung Cancer
  
• Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00068432 - Active, not recruiting
  recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00398385 - Recruiting
  Lung Cancer
  
• Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
  ClinicalTrials.gov Identifier: NCT00388154 - Recruiting
  Endometrial Cancer
  
• Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
  ClinicalTrials.gov Identifier: NCT00123825 - Completed
  Gallbladder Cancer; Biliary Tract Cancer
  
• Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00002998 - Completed
  stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
  ClinicalTrials.gov Identifier: NCT00004090 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
  ClinicalTrials.gov Identifier: NCT00006482 - Completed
  recurrent cervical cancer; cervical squamous cell carcinoma; stage IVA cervical cancer; stage IVB cervical cancer
  
• Gemcitabine and Dasatinib in Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00429234 - Recruiting
  Advanced Cancer; Solid Tumors
  
• Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00075517 - Active, not recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; Adenocarcinoma of the Lung; large cell lung cancer; ...
  
• Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
  ClinicalTrials.gov Identifier: NCT00276549 - Active, not recruiting
  Prostate Cancer
  
• Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00248560 - Recruiting
  Head and Neck Cancer
  
• Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
  ClinicalTrials.gov Identifier: NCT00114218 - Suspended
  uterine carcinosarcoma; recurrent uterine sarcoma
  
• Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
  ClinicalTrials.gov Identifier: NCT00073983 - Recruiting
  recurrent tumors of the Ewing's family; Chondrosarcoma; recurrent osteosarcoma
  
• Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00278460 - Completed
  Lung Cancer
  
• Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
  ClinicalTrials.gov Identifier: NCT00227721 - Recruiting
  Ovarian Cancer; Peritoneal Cavity Cancer
  
• Gemcitabine and Docetaxel to Treat Bone and Soft Tissue Cancers
  ClinicalTrials.gov Identifier: NCT00070772 - Recruiting
  Osteosarcoma; Sarcoma, Ewing's; Chondrosarcoma
  
• Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00509665 - Recruiting
  Head and Neck Cancer
  
• Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
  ClinicalTrials.gov Identifier: NCT00017186 - Active, not recruiting
  localized malignant mesothelioma; advanced malignant mesothelioma; recurrent malignant mesothelioma
  
• Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
  ClinicalTrials.gov Identifier: NCT00072436 - Recruiting
  unspecified adult solid tumor, protocol specific
  
• Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
  ClinicalTrials.gov Identifier: NCT00388349 - Recruiting
  Hodgkin's Disease; Lymphoma
  
• Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
  ClinicalTrials.gov Identifier: NCT00173862 - Completed
  Transitional Cell Carcinoma
  
• Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00323362 - Recruiting
  Lung Cancer
  
• Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
  ClinicalTrials.gov Identifier: NCT00066781 - Active, not recruiting
  adenocarcinoma of unknown primary; newly diagnosed carcinoma of unknown primary; squamous cell carcinoma of unknown primary; ...
  
• Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00089128 - Active, not recruiting
  transitional cell carcinoma of the bladder; recurrent bladder cancer; stage III bladder cancer; stage IV bladder cancer
  
• Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00089102 - Active, not recruiting
  recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
  
• Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00401128 - Completed
  Kidney Cancer
  
• Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
  ClinicalTrials.gov Identifier: NCT00012363 - Active, not recruiting
  stage IV gastric cancer; recurrent gastric cancer; stage IV esophageal cancer; recurrent esophageal cancer; adenocarcinoma of the stomach; ...
  
• Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
  ClinicalTrials.gov Identifier: NCT00006467 - Completed
  recurrent pancreatic cancer; stage IVA pancreatic cancer; duct cell adenocarcinoma of the pancreas; stage III pancreatic cancer; ...
  
• Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005991 - Completed
  stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00268242 - Recruiting
  Adult Acute Erythroid Leukemia; Adult Acute Monoblastic and Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia
  
• Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
  ClinicalTrials.gov Identifier: NCT00003797 - Active, not recruiting
  recurrent pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
  ClinicalTrials.gov Identifier: NCT00436800 - Active, not recruiting
  Nasopharyngeal Neoplasms
  
• Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
  ClinicalTrials.gov Identifier: NCT00276861 - Active, not recruiting
  Colorectal Cancer
  
• Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00305786 - Recruiting
  Lung Cancer
  
• Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00275119 - Active, not recruiting
  Pancreatic Cancer
  
• Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
  ClinicalTrials.gov Identifier: NCT00250822 - Active, not recruiting
  Liver Cancer
  
• Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00006117 - Active, not recruiting
  stage III pancreatic cancer; stage IV pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
  ClinicalTrials.gov Identifier: NCT00274859 - Recruiting
  Unspecified Adult Solid Tumor, Protocol Specific
  
• Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00268411 - Active, not recruiting
  Pancreatic Cancer
  
• Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00536874 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
  ClinicalTrials.gov Identifier: NCT00022633 - Active, not recruiting
  Bladder Cancer; transitional cell cancer of the renal pelvis and ureter; Urethral Cancer
  
• Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
  ClinicalTrials.gov Identifier: NCT00100789 - Active, not recruiting
  Head and Neck Cancer
  
• Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
  ClinicalTrials.gov Identifier: NCT00369629 - Recruiting
  Lymphoma
  
• Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma
  ClinicalTrials.gov Identifier: NCT00191503 - Completed
  Adenocarcinoma
  
• Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00064207 - Active, not recruiting
  adenocarcinoma of the pancreas; stage I pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer
  
• Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
  ClinicalTrials.gov Identifier: NCT00010166 - Completed
  stage I pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
  ClinicalTrials.gov Identifier: NCT00544193 - Active, not recruiting
  Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Pancreatic Cancer; Small Intestine Cancer
  
• Gemcitabine and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00577889 - Not yet recruiting
  Pancreatic Cancer
  
• Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
  ClinicalTrials.gov Identifier: NCT00217555 - Active, not recruiting
  Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
  
• Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00070304 - Active, not recruiting
  recurrent/refractory childhood Hodgkin's lymphoma; childhood lymphocyte predominant Hodgkin's lymphoma; ...
  
• Gemcitabine and/or Erlotinib as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00283244 - Recruiting
  Lung Cancer
  
• Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
  ClinicalTrials.gov Identifier: NCT00191854 - Recruiting
  Breast Neoplasms
  
• Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00049608 - Active, not recruiting
  Breast Cancer; Colorectal Cancer; Lung Cancer; Pancreatic Cancer
  
• Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00003851 - Active, not recruiting
  stage II pancreatic cancer; stage III pancreatic cancer; stage IV pancreatic cancer; Nutrition; adenocarcinoma of the pancreas
  
• Gemcitabine for Marginal Zone Lymphoma
  ClinicalTrials.gov Identifier: NCT00337259 - Recruiting
  Non-Hodgkin's Lymphoma
  
• Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
  ClinicalTrials.gov Identifier: NCT00244933 - Recruiting
  Breast Cancer
  
• Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy
  ClinicalTrials.gov Identifier: NCT00191841 - Completed
  Carcinoma, Non-Small-Cell Lung
  
• Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00112710 - Recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer
  
• Gemcitabine in Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00191334 - Active, not recruiting
  Ovarian Cancer
  
• Gemcitabine in Treating Children With Refractory Solid Tumors
  ClinicalTrials.gov Identifier: NCT00005577 - Completed
  unspecified childhood solid tumor, protocol specific
  
• Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
  ClinicalTrials.gov Identifier: NCT00006462 - Active, not recruiting
  recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia
  
• Gemcitabine in Treating Elderly Women With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00005614 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine in Treating Neoplastic Meningitis in Patients With Leukemia, Lymphoma, or Solid Tumors
  ClinicalTrials.gov Identifier: NCT00052806 - Recruiting
  leptomeningeal metastases
  
• Gemcitabine in Treating Patients With Advanced Colorectal Cancer
  ClinicalTrials.gov Identifier: NCT00007943 - Completed
  recurrent colon cancer; stage III colon cancer; stage III rectal cancer; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer
  
• Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
  ClinicalTrials.gov Identifier: NCT00003744 - Active, not recruiting
  high-grade salivary gland carcinoma; low-grade salivary gland carcinoma; Salivary Gland Cancer
  
• Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
  ClinicalTrials.gov Identifier: NCT00357630 - Active, not recruiting
  Carcinoma of Unknown Primary; Pain
  
• Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma
  ClinicalTrials.gov Identifier: NCT00234026 - Active, not recruiting
  Lymphoma
  
• Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
  ClinicalTrials.gov Identifier: NCT00006224 - Completed
  recurrent cervical cancer; cervical adenocarcinoma; cervical adenosquamous cell carcinoma
  
• Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
  ClinicalTrials.gov Identifier: NCT00234039 - Recruiting
  Recurrent Bladder Cancer; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Transitional Cell Carcinoma of the Bladder
  
• Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00005829 - Active, not recruiting
  refractory chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
  
• Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
  ClinicalTrials.gov Identifier: NCT00017498 - Active, not recruiting
  stage IV salivary gland cancer; recurrent salivary gland cancer; salivary gland adenoid cystic carcinoma; ...
  
• Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00014287 - Completed
  stage I bladder cancer; stage 0 bladder cancer; recurrent bladder cancer
  
• Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
  ClinicalTrials.gov Identifier: NCT00003316 - Completed
  uterine leiomyosarcoma; recurrent uterine sarcoma
  
• Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel
  ClinicalTrials.gov Identifier: NCT00003540 - Active, not recruiting
  stage IV breast cancer; recurrent breast cancer
  
• Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen
  ClinicalTrials.gov Identifier: NCT00191269 - Active, not recruiting
  Metastatic Breast Cancer After Anthracycline, Taxane Regimen
  
• Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00191139 - Active, not recruiting
  Carcinoma, Non Small Cell Lung
  
• Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
  ClinicalTrials.gov Identifier: NCT00410982 - Recruiting
  Leukemia; Lymphoma; Myeloma
  
• Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00004201 - Completed
  stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Gemcitabine plus Carboplatin versus Carboplatin Monotherapy in Patients with Advanced Ovarian Cancer
  ClinicalTrials.gov Identifier: NCT00102414 - Completed
  Ovarian Cancer
  
• Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00003723 - Active, not recruiting
  advanced malignant mesothelioma; sarcomatous mesothelioma; epithelial mesothelioma
  
• Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00003928 - Active, not recruiting
  Stage IV Renal Cell Cancer; recurrent renal cell cancer
  
• Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
  ClinicalTrials.gov Identifier: NCT00006028 - Active, not recruiting
  recurrent ovarian epithelial cancer; peritoneal cavity cancer
  
• Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes
  ClinicalTrials.gov Identifier: NCT00192101 - Completed
  Metastatic Breast Cancer
  
• Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer
  ClinicalTrials.gov Identifier: NCT00006010 - Active, not recruiting
  localized unresectable adult primary liver cancer; advanced adult primary liver cancer; recurrent adult primary liver cancer; ...
  
• Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00004139 - Active, not recruiting
  stage IV non-small cell lung cancer; Squamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; stage IIIB non-small cell lung cancer; ...
  
• Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin,in Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00564720 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00007917 - Active, not recruiting
  unspecified adult solid tumor, protocol specific
  
• Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
  ClinicalTrials.gov Identifier: NCT00201305 - Completed
  Biliary Tract Disease
  
• Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV NSCLC
  ClinicalTrials.gov Identifier: NCT00453115 - Recruiting
  Lung Cancer
  
• Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00004190 - Completed
  recurrent pancreatic cancer; stage IVA pancreatic cancer; duct cell adenocarcinoma of the pancreas; stage III pancreatic cancer; ...
  
• Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
  ClinicalTrials.gov Identifier: NCT00004159 - Completed
  stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
  ClinicalTrials.gov Identifier: NCT00059865 - Active, not recruiting
  advanced adult primary liver cancer; unresectable gallbladder cancer; unresectable extrahepatic bile duct cancer; ...
  
• Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00003426 - Completed
  stage II pancreatic cancer; stage III pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00003546 - Active, not recruiting
  stage III pancreatic cancer; adenocarcinoma of the pancreas; stage I pancreatic cancer; stage II pancreatic cancer
  
• Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00003202 - Completed
  stage IIIA non-small cell lung cancer; Adenosquamous Cell Lung Cancer; Squamous Cell Lung Cancer; stage IIIB non-small cell lung cancer; ...
  
• Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00022009 - Active, not recruiting
  stage IIIA non-small cell lung cancer; stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer
  
• Gemcitabine With Curcumin for Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00192842 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00088894 - Active, not recruiting
  adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
  
• Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00030732 - Active, not recruiting
  stage III pancreatic cancer; recurrent pancreatic cancer; adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00032175 - Completed
  stage III pancreatic cancer; duct cell adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without cBR96-Doxorubicin Immunoconjugate (SGN-15) in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer
  ClinicalTrials.gov Identifier: NCT00056017 - Suspended
  recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; ovarian endometrioid adenocarcinoma; ...
  
• Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas
  ClinicalTrials.gov Identifier: NCT00075686 - Active, not recruiting
  adenocarcinoma of the pancreas; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00005093 - Active, not recruiting
  stage IIIA non-small cell lung cancer; stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; ...
  
• Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00004861 - Active, not recruiting
  stage II pancreatic cancer; stage IVA pancreatic cancer; stage III pancreatic cancer; stage IVB pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
  ClinicalTrials.gov Identifier: NCT00262769 - Recruiting
  Extrahepatic Bile Duct Cancer; Gallbladder Cancer
  
• Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00416507 - Active, not recruiting
  Pancreatic Cancer
  
• Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00462852 - Recruiting
  Pancreatic Cancer; Thromboembolism
  
• Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00031837 - Active, not recruiting
  adenocarcinoma of the pancreas; Pancreatic Cancer; Quality of Life; Thromboembolism
  
• Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
  ClinicalTrials.gov Identifier: NCT00227669 - Recruiting
  Sarcoma
  
• Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00026338 - Active, not recruiting
  stage III pancreatic cancer; adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00023972 - Active, not recruiting
  stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
  ClinicalTrials.gov Identifier: NCT00323791 - Completed
  Kidney Cancer
  
• Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00323063 - Recruiting
  Breast Cancer
  
• Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00058149 - Active, not recruiting
  stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
  ClinicalTrials.gov Identifier: NCT00075452 - Active, not recruiting
  adenocarcinoma of the pancreas; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer
  
• Gemcitabine With or Without Pemetrexed Disodium in Treating Patients With Unresectable Stage II, Stage III, or Stage IV Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00049426 - Active, not recruiting
  stage II pancreatic cancer; stage III pancreatic cancer; stage IVB pancreatic cancer; stage IVA pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine With or Without R115777 in Treating Patients With Advanced Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00005648 - Active, not recruiting
  recurrent pancreatic cancer; stage II pancreatic cancer; stage IVA pancreatic cancer; stage III pancreatic cancer; stage IVB pancreatic cancer; ...
  
• Gemcitabine With or Without Radiation Therapy in Treating Patients with Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00057876 - Active, not recruiting
  stage III pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00541021 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00499265 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00251355 - Terminated
  Pancreatic Cancer
  
• Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00366457 - Recruiting
  Pancreatic Cancer; Adenocarcinoma of the Pancreas
  
• Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00460174 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00100815 - Active, not recruiting
  adenocarcinoma of the pancreas; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer
  
• Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00524069 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
  ClinicalTrials.gov Identifier: NCT00496704 - Recruiting
  Colorectal Cancer
  
• Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00016315 - Active, not recruiting
  stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer
  
• Gemcitabine, Carboplatin, and Bortezomib in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00075751 - Active, not recruiting
  stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; recurrent non-small cell lung cancer
  
• Gemcitabine, Carboplatin, and Dexamethasone With or Without Rituximab in Treating Patients With Relapsed or Primary Refractory Lymphoma
  ClinicalTrials.gov Identifier: NCT00072514 - Completed
  Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; anaplastic large cell lymphoma; angioimmunoblastic T-cell lymphoma; Cutaneous T-Cell Lymphoma; ...
  
• Gemcitabine, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
  ClinicalTrials.gov Identifier: NCT00467116 - Suspended
  Pancreatic Cancer
  
• Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00006105 - Active, not recruiting
  stage II bladder cancer; stage III bladder cancer; stage IV bladder cancer; Drug Toxicity
  
• Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00126633 - Active, not recruiting
  stage IVA pancreatic cancer; stage IVB pancreatic cancer; adenocarcinoma of the pancreas
  
• Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00176813 - Active, not recruiting
  Pancreatic Cancer
  
• Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00090909 - Completed
  recurrent adult Hodgkin's lymphoma
  
• Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00103051 - Active, not recruiting
  stage IIIA non-small cell lung cancer
  
• Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
  ClinicalTrials.gov Identifier: NCT00335543 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer
  ClinicalTrials.gov Identifier: NCT00556621 - Recruiting
  Bladder Cancer
  
• Gemcitabine, Dexamethasone and Cisplatin Versus Dexamethasone, Cytarabine, Cisplatin in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
  ClinicalTrials.gov Identifier: NCT00089817 - Recruiting
  Lymphoma
  
• Gemcitabine, Docetaxel, and Capecitabine in Treating Patients with Cancer of Unknown Primary Origin
  ClinicalTrials.gov Identifier: NCT00119314 - Active, not recruiting
  newly diagnosed carcinoma of unknown primary; recurrent carcinoma of unknown primary
  
• Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00193453 - Active, not recruiting
  Lung Cancer
  
• Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
  ClinicalTrials.gov Identifier: NCT00004066 - Active, not recruiting
  adult soft tissue sarcoma; ovarian sarcoma; small intestine cancer; uterine sarcoma
  
• Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients.
  ClinicalTrials.gov Identifier: NCT00128856 - Completed
  Breast Cancer
  
• Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
  ClinicalTrials.gov Identifier: NCT00005926 - Completed
  Pancreatic Cancer; Pancreatic Neoplasm
  
• Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
  ClinicalTrials.gov Identifier: NCT00417976 - Recruiting
  Pancreatic Cancer
  
• Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma.
  ClinicalTrials.gov Identifier: NCT00350961 - Recruiting
  Cholangiocarcinoma
  
• Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00242190 - Active, not recruiting
  Pancreatic Neoplasms
  
• Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00191568 - Completed
  Pancreatic Neoplasms
  
• Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
  ClinicalTrials.gov Identifier: NCT00361231 - Recruiting
  Biliary Tract Adenocarcinoma; Galbladder Adenocarcinoma
  
• Gemcitabine, Oxaliplatin in Combination with Bevacizumab in Patients with Hepatocellular Carcinoma
  ClinicalTrials.gov Identifier: NCT00142467 - Active, not recruiting
  Hepatocellular Carcinoma
  
• Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
  ClinicalTrials.gov Identifier: NCT00310011 - Active, not recruiting
  Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
  
• Gemcitabine, Paclitaxel, Doxorubicin, and Pegfilgrastim in Treating Patients With Metastatic or Unresectable Bladder Cancer or Urinary Tract Cancer and Kidney Dysfunction
  ClinicalTrials.gov Identifier: NCT00478361 - Recruiting
  Bladder Cancer; Neutropenia; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
  
• Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
  ClinicalTrials.gov Identifier: NCT00551122 - Recruiting
  Brain and Central Nervous System Tumors; Extragonadal Germ Cell Tumor; Ovarian Cancer; Testicular Germ Cell Tumor
  
• Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00201760 - Recruiting
  Breast Cancer
  
• Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
  ClinicalTrials.gov Identifier: NCT00551096 - Recruiting
  Advanced Solid Tumors; Biliary Cancer; Pancreatic Cancer
  
• Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00536614 - Completed
  Pancreatic Cancer
  
• Gemcitabine/Cisplatin Vs Gemcitabine/Epirubicin for NSCLC
  ClinicalTrials.gov Identifier: NCT00154739 - Recruiting
  Non-small cell lung cancer
  
• Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
  ClinicalTrials.gov Identifier: NCT00193596 - Recruiting
  Neoplasms, Unknown Primary
  
• Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-small Cell Lung Cancer (NSCLC)
  ClinicalTrials.gov Identifier: NCT00087802 - Active, not recruiting
  Carcinoma, Non-Small-Cell Lung
  
• Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
  ClinicalTrials.gov Identifier: NCT00191230 - Completed
  Carcinoma, Non Small Cell Lung
  
• Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer
  ClinicalTrials.gov Identifier: NCT00480597 - Active, not recruiting
  Metastatic Breast Cancer
  
• Gemox as First and Second Line Therapy in Unknown Primary Cancer
  ClinicalTrials.gov Identifier: NCT00353145 - Active, not recruiting
  Unknown Primary Neoplasms
  
• GEMOX: Oxaliplatin in Pancreatic Cancer
  ClinicalTrials.gov Identifier: NCT00261092 - Completed
  Pancreatic Neoplasms
  
• Gemtuzumab and Combination Chemothearpy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
  ClinicalTrials.gov Identifier: NCT00551460 - Not yet recruiting
  Leukemia
  
• Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
  ClinicalTrials.gov Identifier: NCT00022321 - Active, not recruiting
  Refractory Anemia; de novo myelodysplastic syndromes; refractory anemia with ringed sideroblasts; ...
  
• Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00089050 - Completed
  adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia
  
• Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00006265 - Active, not recruiting
  recurrent adult acute myeloid leukemia
  
• Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00460447 - Recruiting
  Acute Myeloid Leukemia; Allogeneic Transplantation
  
• Gemtuzumab Ozogamicin in Combination with A-HAM in Refractory AML (GO-A-HAM)
  ClinicalTrials.gov Identifier: NCT00143975 - Active, not recruiting
  Leukemia, Myeloid, Acute
  
• Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
  ClinicalTrials.gov Identifier: NCT00091234 - Active, not recruiting
  adult acute erythroid leukemia; adult acute monoblastic and acute monocytic leukemia; adult acute myeloid leukemia; secondary acute myeloid leukemia
  
• Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia After Stem Cell Transplantation
  ClinicalTrials.gov Identifier: NCT00053274 - Completed
  recurrent adult acute myeloid leukemia; recurrent childhood acute myeloid leukemia; secondary acute myeloid leukemia
  
• Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
  ClinicalTrials.gov Identifier: NCT00070174 - Completed
  childhood acute monocytic leukemia; childhood acute myelo